The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
International Union of Basic and Clinical Pharmacology. CVI: GABAA Receptor Subtype- and Function-selective Ligands: Key Issues in Translation to Humans
Open accessAbstract
GABAA receptors are the major inhibitory transmitter receptors in the brain. They are ligand-gated chloride channels and the site of action of benzodiazepines, barbiturates, neuroactive steroids, anesthetics, and convulsants. GABAA receptors are composed of five subunits that can belong to different subunit classes. The existence of 19 homologous subunits and their distinct regional, cellular, and subcellular distribution gives rise to a large number of GABAA receptor subtypes with distinct pharmacology, which modulate different functions of the brain. A variety of compounds have been identified that were claimed to modulate selectively individual GABAA receptor subtypes. However, many of these compounds have only incompletely been investigated or, in addition to a preferential modulation of a receptor subtype, also modulate other subtypes at similar concentrations. Although their differential efficacy at distinct receptor subtypes reduced side effects in behavioral experiments in rodents, the exact receptor subtypes mediating their behavioral effects cannot be unequivocally delineated. In addition, the discrepant in vivo effects of some of these compounds in rodents and man raised doubts on the applicability of the concept of receptor subtype selectivity as a guide for the development of clinically useful drugs. Here, we provide an up-to-date review on the currently available GABAA receptor subtype-selective ligands. We present data on their actual activity at GABAA receptor subtypes, discuss the translational aspect of subtype-selective drugs, and make proposals for the future development of ligands with better anxioselectivity in humans. Finally, we discuss possible ways to strengthen the conclusions of behavioral studies with the currently available drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors
Farrant, M., & Nusser, Z. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1625 · Cited by 2,081 · cited 2×
“…To Modulate Selectively d-Containing GABAA Receptors GABAA receptors containing d subunits seem to be exclusively located extrasynaptically (Nusser et al., 1998) and contribute to the tonic inhibition of neurons in the brain that modulates both cell and network behavior (Farrant and Nusser, 2005).”
BackgroundBenzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Neurosteroids: endogenous regulators of the GABAA receptor
Belelli, D., & Lambert, J. J. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1703 · Cited by 1,159 · cited 2×
“, 2014) together with the observation that extrasynaptic receptors containing a4 and d subunits seem to be involved in inducing sedation and sleep (Belelli and Lambert, 2005; Belelli et al., 2005) and possibly also anxiety (Marowsky and Vogt, 2014) indicate that modulation of such receptors can contribute to the overa…”
BackgroundMolecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke
Clarkson, A. N., Huang, B. S., MacIsaac, S. E., Mody, I., & Carmichael, S. T. (2010) · Nature · doi:10.1038/nature09511 · Cited by 869 · cited 1×
“Other experiments indicated that reducing excessive tonic inhibition by negative allosteric modulators at a5bg2 receptors may promote functional recovery from stroke (Clarkson et al., 2010).”
BackgroundBeyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes
Rudolph, U., & Knoflach, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3502 · Cited by 733 · cited 2×
“…the mutations a1H101R, a3H126R, or a5H105R that are also used for demonstrating the function of the respective receptor subtypes in the brain (Rudolph and Knoflach, 2011; Rudolph and Möhler, 2014), other ligands of the benzodiazepine site, such as bretazenil or Ro15-4513, are even more…”
BackgroundCollinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05572.2002 · Cited by 628 · cited 6×
“…the sedative effects (Rudolph et al., 1999; McKernan et al., 2000) and a5bg2 receptors the cognition-impairing effects of classic benzodiazepines (Collinson et al., 2002; Crestani et al., 2002), avoiding modulation of both of these receptor types was another major goal of pharmaceutical industry.”
BackgroundInfluentialJurd, R., Arrasa, M., Lambert, S., Drexler, B., Siegwart, R., Crestani, F., Zaugg, M., Vogt, K. E., Ledermann, B., Antkowiak, B., et al. (2003) · The FASEB Journal · doi:10.1096/fj.02-0611fje · Cited by 558
Reversal of pathological pain through specific spinal GABAA receptor subtypes
Knabl, J., Witschi, R., Hösl, K., Reinold, H., Zeilhofer, U. B., Ahmadi, S., Brockhaus, J., Sergejeva, M., Hess, A., Brune, K., et al. (2008) · Nature · doi:10.1038/nature06493 · Cited by 438 · cited 2×
“…(Löw et al., 2000). a2bg2 together with a3bg2 receptors seem to mediate some antinociceptive and muscle relaxant actions (Crestani et al., 2001;Knabl et al., 2008; Ralvenius et al., 2015), and a5bg2 receptors mediate the cognitive effects of benzodiazepine site ligands (Collinson et al.,…”
BackgroundExtending animal models of fear conditioning to humans
Delgado, M. R., Olsson, A., & Phelps, E. A. (2006) · Biological Psychology · doi:10.1016/j.biopsycho.2006.01.006 · Cited by 366
Activation of GABAA Receptors: Views from Outside the Synaptic Cleft
Glykys, J., & Mody, I. (2007) · Neuron · doi:10.1016/j.neuron.2007.11.002 · Cited by 358 · cited 1×
“The GABA concentrations acting at extrasynaptic GABAA receptors (0.2–2.5 mM; Glykys and Mody, 2007b) activate extrasynaptic as well as synaptic receptors, although to a different extent (Mortensen et al., 2012; Karim et al., 2013).”
BackgroundInfluentialRudolph, U., & Möhler, H. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135947 · Cited by 319
Sedation and Anesthesia Mediated by Distinct GABA A Receptor Isoforms
Reynolds, D. S., Rosahl, T. W., Cirone, J., O'Meara, G. F., Haythornthwaite, A., Newman, R. J., Myers, J., Sur, C., Howell, O., Rutter, A. R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-24-08608.2003 · Cited by 318 · cited 5×
“In contrast, both the immobilizing action of etomidate and of propofol and their induction of respiratory depression seem to be mediated via b3-containing receptors (Jurd et al., 2003; Reynolds et al., 2003; Zeller et al., 2005, 2007).”
BackgroundInfluentialDias, R., Sheppard, W. F. A., Fradley, R. L., Garrett, E. M., Stanley, J. L., Tye, S. J., Goodacre, S., Lincoln, R. J., Cook, S. M., Conley, R., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1166-05.2005 · Cited by 247
Patterns of mRNA and protein expression for 12 GABAA receptor subunits in the mouse brain
Hörtnagl, H., Tasan, R. O., Wieselthaler, A., Kirchmair, E., Sieghart, W., & Sperk, G. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.01.008 · Cited by 229
Self-citationRegulating anxiety with extrasynaptic inhibition
Botta, P., Demmou, L., Kasugai, Y., Markovic, M., Xu, C., Fadok, J. P., Lu, T., Poe, M. M., Xu, L., Cook, J. M., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4102 · Cited by 192 · cited 1×
“In addition, evidence is accumulating that not only a2-containing receptor subtypes, but also a5- (Botta et al., 2015; Behlke et al., 2016)- or a4- and d-containing receptor subtypes (Marowsky and Vogt, 2014) contribute to the modulation of anxiety.”
BackgroundCrystal structures of a GABAA-receptor chimera reveal new endogenous neurosteroid-binding sites.
Laverty, D., Thomas, P., Field, M., Andersen, O. J., Gold, M. G., Biggin, P. C., Gielen, M., & Smart, T. G. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3477 · Cited by 179 · cited 2×
“The anxiolytic, sedative, and anticonvulsant neurosteroids seem to act via several neurosteroid binding sites in the transmembrane domain of GABAA receptors that still have not been unequivocally identified and might differ in different receptor subtypes (Seljeset et al., 2015; Laverty et al., 2017).”
BackgroundEbert, B., Thompson, S. A., Saounatsou, K., McKernan, R., Krogsgaard-Larsen, P., & Wafford, K. A. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.6.1150 · Cited by 145
de Haas, S. L., de Visser, S. J., van der Post, J. P., de Smet, M., Schoemaker, R. C., Rijnbeek, B., Cohen, A. F., Vega, J. M., Agrawal, N. G. B., Goel, T. V., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106072343 · Cited by 84
Engin, E., Zarnowska, E. D., Benke, D., Tsvetkov, E., Sigal, M., Keist, R., Bolshakov, V. Y., Pearce, R. A., & Rudolph, U. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1370-15.2015 · Cited by 79
Christian, E. P., Snyder, D. H., Song, W., Gurley, D. A., Smolka, J., Maier, D. L., Ding, M., Gharahdaghi, F., Liu, X. F., Chopra, M., et al. (2015) · Journal of Neurophysiology · doi:10.1152/jn.00539.2013 · Cited by 68
Primus, R. J., Yu, J., Xu, J., Hartnett, C., Meyyappan, M., Kostas, C., Ramabhadran, T. V., & Gallager, D. W. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12410-5 · Cited by 60 · cited 1×
“Since drug efficacy plays a critical role in determining the degree of GABAA receptor uncoupling, and, perhaps in the development of tolerance and dependence (Primus et al., 1996), low efficacy drugs might have an added benefit in a long-term treatment of patients.”
BackgroundBlanchard, D. C., Summers, C. H., & Blanchard, R. J. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.06.008 · Cited by 60
Griebel, G., Perrault, G., Simiand, J., Cohen, C., Granger, P., Decobert, M., Françon, D., Avenet, P., Depoortere, H., Tan, S., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29437-4 · Cited by 59
Atack, J. R., Wong, D. F., Fryer, T. D., Ryan, C., Sanabria, S., Zhou, Y., Dannals, R. F., Eng, W.-S., Gibson, R. E., Burns, H. D., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157909 · Cited by 36
Pharmacological Properties of DOV 315,090, an ocinaplon metabolite
Berezhnoy, D., Gravielle, M. C., Downing, S., Kostakis, E., Basile, A. S., Skolnick, P., Gibbs, T. T., & Farb, D. H. (2008) · BMC Pharmacology · doi:10.1186/1471-2210-8-11 · Cited by 18 · cited 3×
“But how can ocinaplon act as a selective anxiolytic in rodents and humans (Czobor et al., 2010), although it 870 Sieghart and Savi c seems not to be receptor subtype selective at all (Lippa et al., 2005; Berezhnoy et al., 2008)?”
Background
Cited by
Single-particle cryo-EM at atomic resolution
Nakane, T., Kotecha, A., Sente, A., McMullan, G., Masiulis, S., Brown, P. M. G. E., Grigoras, I. T., Malinauskaite, L., Malinauskas, T., Miehling, J., et al. (2020) · Nature · doi:10.1038/s41586-020-2829-0 · Cited by 868
Shared structural mechanisms of general anaesthetics and benzodiazepines
Kim, J. J., Gharpure, A., Teng, J., Zhuang, Y., Howard, R. J., Zhu, S., Noviello, C. M., Walsh, R. M., Lindahl, E., & Hibbs, R. E. (2020) · Nature · doi:10.1038/s41586-020-2654-5 · Cited by 382
Lüscher, B., & Möhler, H. (2019) · F1000Research · doi:10.12688/f1000research.18758.1 · Cited by 105
Harbourt, K., Nevo, O. N., Zhang, R., Chan, V., & Croteau, D. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5004 · Cited by 46
Troppoli, T. A., Zanos, P., Georgiou, P., Gould, T. D., Rudolph, U., & Thompson, S. M. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.11.024 · Cited by 29
Metadata
- Authors
- Sieghart, W., & Savić, M. M.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 70
- Issue
- 4
- Pages
- 836-878
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2892382057
- Cited by
- 210
- References
- 27
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.